Ultra Violette recalled 44,497 tubes of its Mini SPF Mates kit on August 22, 2025. The sunscreen products showed inconsistent SPF results, including readings as low as SPF 4. Consumers must stop use immediately and contact the distributor for guidance.
Subpotent/Super-potent Product: Testing of the SPF 50 sunscreen revealed inconsistency in SPF results ranging from SPF 4, 10, 21, 26, 33, 60, 61, and 64.
Consumers and healthcare providers should stop using this product immediately. Contact GRACE & FIRE PTY LTD or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled product is the Ultra Violette Mini SPF Mates kit, which includes Velvet Screen SPF 50 and Supreme Sunscreen SPF 50. The products were distributed by Grace & Fire USA Inc. The lot numbers affected are A2453 and A2454, with expiration dates of November 30, 2026, and December 31, 2026.
Testing revealed the SPF 50 sunscreen's effectiveness varied greatly, with some tests showing SPF levels as low as 4. This inconsistency poses a significant risk to consumers relying on these products for sun protection.
There are no reported injuries or incidents associated with the recalled products at this time. However, the potential for inadequate sun protection is a serious concern.
Consumers should stop using the affected products immediately. For further guidance, contact GRACE & FIRE PTY LTD or consult your healthcare provider.
For more information, visit the FDA website at https://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?recall_number=D-0641-2025. Consumers can also reach out to the distributor for assistance.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.